PDS Biotechnology Corporation (Nasdaq: PDSB) has announced its financial results for the third quarter of 2026, revealing significant developments in its business and clinical programs. The company reported a PIPE financing of up to $22.3 million, led by Nant Capital, LLC, which underscores its commitment to advancing its innovative immunotherapy initiatives.

The announcement, made on November 13, 2026, highlights the company’s ongoing efforts to prioritize its lead development program, PDS0301, an investigational tumor-targeted IL-12 immunocytokine. Frank Bedu-Addo, Ph.D., President and CEO of PDS Biotech, expressed optimism about the potential of targeted T cell immunotherapy to transform the treatment of solid tumors. He noted the support from Dr. Soon-Shiong and NantWorks, which has been instrumental in the recent financing efforts.

Background

PDS Biotechnology Corp is a clinical-stage immunotherapy company based in Princeton, New Jersey, specializing in pharmaceutical preparations. The company trades on the Nasdaq under the ticker symbol PDSB and operates as a smaller reporting company. PDS Biotech focuses on developing therapies that harness the immune system to combat cancer.

What the Filing Says

According to the SEC filing, the company reported, "During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program." The press release attached to the filing also detailed the initial closing of a PIPE financing led by Nant Capital, which includes a contingent milestone closing related to the submission of a Phase 3 clinical trial protocol for PDS0301.

Impact

This update may significantly affect PDS Biotech’s operations and its ability to attract further investments. The PIPE financing and strategic partnerships with NantWorks and other investors could enhance the company’s clinical development capabilities and market positioning. Additionally, the appointment of experienced pharmaceutical veterans to its board is expected to strengthen its governance and strategic direction.

What's Next

The filing does not say what happens next. However, the company is likely to continue its clinical trials and further engage with investors as it progresses with its immunotherapy programs.